Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil ROCK inhibition as disease-modifying treatment for ALS
DRKS00013948Phase 2Completed
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of fasudil in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Georg-August-Universität Göttingen. Started Jan 2019; status: completed.
02
Drugs
fasudil
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on DRKS00013948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013948.